Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00336453 · ClinicalTrials.gov registry record · Phase 1
Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics
A Phase 1 study of Influenza, sponsored by Protein Sciences Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 156
- Enrollment target
- 3
- Study locations
NCT00336453: Completed Phase 1 study of Influenza, sponsored by Protein Sciences Corporation.
NCT00336453 is a Phase 1 study of Influenza that has completed, run by Protein Sciences Corporation. The registered enrollment target is 156 participants, below the 36,803-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00336453, a Phase 1 study of Influenza, has completed, sponsored by Protein Sciences Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 156 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study was to evaluate dose-related safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine, administered to healthy children aged 6 to 59 months.
Conditions Studied
Interventions
- BIOLOGICAL Influenza Vaccination
Study Locations (3)
Kentucky
- Kentucky pediatric /Adult Research - Bardstown
Missouri
- Saint Louis University - St Louis
Pennsylvania
- Primary Physicians Research - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-07 |
| Phase | Phase 1 |
What the finished NCT00336453 record still lists
NCT00336453 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, below the 36,803-participant average among 156 other Influenza trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 1 intervention - of which Influenza Vaccination is the first listed.
NCT00336453 reports a single indexed study location in Kentucky, Missouri, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00336453 about?
NCT00336453 is a clinical study titled "Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics". The purpose of this study was to evaluate dose-related safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine, administered to healthy children aged 6 to 59 months.
What is the current status of trial NCT00336453?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 156 participants. The study started on 2006-10. Estimated completion is 2007-07.
What conditions does trial NCT00336453 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT00336453?
The interventions under investigation include: Influenza Vaccination (BIOLOGICAL).
Who is sponsoring clinical trial NCT00336453?
This trial is sponsored by Protein Sciences Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00336453 being conducted?
This trial has 3 study locations across Kentucky, Missouri, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00336453's enrollment target sits among peer trials
156 88th of 156 higher than 69 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
pH1N1 Blinded Challenge Study
RECRUITING · Phase 1
-
A/Texas Flu Challenge
RECRUITING · Phase 1
-
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
RECRUITING · Phase 1
-
Influenza Human Challenge Model
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
ACTIVE NOT RECRUITING · Phase 1
-
Pilot Influenza Challenge Study
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia